326 related articles for article (PubMed ID: 20555127)
41. Method for radioiodination of proteins using N-succinimidyl 3-hydroxy-4-iodobenzoate.
Vaidyanathan G; Affleck DJ; Zalutsky MR
Bioconjug Chem; 1997; 8(5):724-9. PubMed ID: 9327137
[TBL] [Abstract][Full Text] [Related]
42. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
43. Direct radiolabeling of monoclonal antibodies with generator-produced rhenium-188 for radioimmunotherapy: labeling and animal biodistribution studies.
Griffiths GL; Goldenberg DM; Knapp FF; Callahan AP; Chang CH; Hansen HJ
Cancer Res; 1991 Sep; 51(17):4594-602. PubMed ID: 1873804
[TBL] [Abstract][Full Text] [Related]
44. Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate.
Schuster JM; Garg PK; Bigner DD; Zalutsky MR
Cancer Res; 1991 Aug; 51(16):4164-9. PubMed ID: 1714341
[TBL] [Abstract][Full Text] [Related]
45. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
[TBL] [Abstract][Full Text] [Related]
46. Attachment of an anti-MUC1 monoclonal antibody to 5-FU loaded BSA nanoparticles for active targeting of breast cancer cells.
Kouchakzadeh H; Shojaosadati SA; Mohammadnejad J; Paknejad M; Rasaee MJ
Hum Antibodies; 2012; 21(3-4):49-56. PubMed ID: 23549021
[TBL] [Abstract][Full Text] [Related]
47. Epitope mapping of PR81 anti-MUC1 monoclonal antibody following PEPSCAN and phage display techniques.
Mohammadi M; Rasaee MJ; Rajabibazl M; Paknejad M; Zare M; Mohammadzadeh S
Hybridoma (Larchmt); 2007 Aug; 26(4):223-30. PubMed ID: 17725384
[TBL] [Abstract][Full Text] [Related]
48. Production of monoclonal antibody, PR81, recognizing the tandem repeat region of MUC1 mucin.
Paknejad M; Rasaee MJ; Tehrani FK; Kashanian S; Mohagheghi MA; Omidfar K; Bazl MR
Hybrid Hybridomics; 2003 Jun; 22(3):153-8. PubMed ID: 12954100
[TBL] [Abstract][Full Text] [Related]
49. Clinical-scale radiolabeling of a humanized anticarcinoembryonic antigen monoclonal antibody, hMN-14, with residualizing 131I for use in radioimmunotherapy.
Govindan SV; Griffiths GL; Stein R; Andrews P; Sharkey RM; Hansen HJ; Horak ID; Goldenberg DM
J Nucl Med; 2005 Jan; 46(1):153-9. PubMed ID: 15632046
[TBL] [Abstract][Full Text] [Related]
50. Preparation and preclinical characterization of
Alirezapour B; Ashkezari MD; Fini MM; Rasaee MJ; Mohammadnejad J; Paknejad M; Maadi E; Yousefnia H; Zolghadri S
J Cancer Res Ther; 2022; 18(1):158-167. PubMed ID: 35381778
[TBL] [Abstract][Full Text] [Related]
51. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody.
Denardo SJ; O'Grady LF; Richman CM; Goldstein DS; O'Donnell RT; Denardo DA; Kroger LA; Lamborn KR; Hellström KE; Hellström I; Denardo GL
Anticancer Res; 1997; 17(3B):1745-51. PubMed ID: 9179228
[TBL] [Abstract][Full Text] [Related]
52. A new competitive enzyme linked immunosorbent assay (MRP83-CA15-3) for MUC1 measurement in breast cancer.
Mohammadnejad J; Rasaee MJ; Saqhafi B; Rajabibazl M; Rahbarizadeh F; Omidfar K; Paknejad M
J Immunoassay Immunochem; 2006; 27(2):139-49. PubMed ID: 16711252
[TBL] [Abstract][Full Text] [Related]
53. Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer.
Rasaneh S; Rajabi H; Babaei MH; Daha FJ; Salouti M
Nucl Med Biol; 2009 May; 36(4):363-9. PubMed ID: 19423003
[TBL] [Abstract][Full Text] [Related]
54. Comparison of the biodistribution and the efficacy of monoclonal antibody 323/A3 labeled with either 131I or 186Re in human ovarian cancer xenografts.
Kievit E; van Gog FB; Schlüper HM; van Dongen GA; Pinedo HM; Boven E
Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):813-23. PubMed ID: 9240651
[TBL] [Abstract][Full Text] [Related]
55. Tissue and serum MUC1 mucin detection in breast cancer patients.
Croce MV; Isla-Larrain MT; Demichelis SO; Gori JR; Price MR; Segal-Eiras A
Breast Cancer Res Treat; 2003 Oct; 81(3):195-207. PubMed ID: 14620915
[TBL] [Abstract][Full Text] [Related]
56. Design, synthesis, radiolabeling and in vitro and in vivo characterization of tumor-antigen- and antibody-derived peptides for the detection of breast cancer.
Okarvi SM; Jammaz IA
Anticancer Res; 2009 Apr; 29(4):1399-409. PubMed ID: 19414394
[TBL] [Abstract][Full Text] [Related]
57. A Mucin1 C-terminal Subunit-directed Monoclonal Antibody Targets Overexpressed Mucin1 in Breast Cancer.
Wu G; Kim D; Kim JN; Park S; Maharjan S; Koh H; Moon K; Lee Y; Kwon HJ
Theranostics; 2018; 8(1):78-91. PubMed ID: 29290794
[No Abstract] [Full Text] [Related]
58. Rhenium-186-mercaptoacetyltriglycine-labeled monoclonal antibody for radioimmunotherapy: in vitro assessment, in vivo kinetics and dosimetry in tumor-bearing nude mice.
Kinuya S; Yokoyama K; Tega H; Hiramatsu T; Konishi S; Yamamoto W; Shuke N; Aburano T; Watanabe N; Takayama T; Michigishi T; Tonami N
Jpn J Cancer Res; 1998 Aug; 89(8):870-8. PubMed ID: 9765625
[TBL] [Abstract][Full Text] [Related]
59. Preparation and evaluation of the tumor-specific antigen-derived synthetic mucin 1 peptide: A potential candidate for the targeting of breast carcinoma.
Okarvi SM; Al Jammaz I
Nucl Med Biol; 2016 Jul; 43(7):403-9. PubMed ID: 27179249
[TBL] [Abstract][Full Text] [Related]
60. In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations.
Steffens MG; Oosterwijk E; Kranenborg MH; Manders JM; Debruyne FM; Corstens FH; Boerman OC
J Nucl Med; 1999 May; 40(5):829-36. PubMed ID: 10319758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
